Regen BioPharma Inc financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
RGBP, RGBPP on OTC
Location
La Mesa, CA
Fiscal year end
30 September
Latest financial report
13 Feb 2026

Latest SEC snapshot (2025-12-31) highlights Return On Equity 28.2%, Return On Assets -806.1%, and Operating Margin -350.3%.

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

26.3/100

Weak Confidence medium

Return On Equity

28%

Metric score 100.0/100

Return On Assets

-806%

Metric score 0.0/100

Financial Health

Current Ratio
0.03x
Quick Ratio
0.03x

Strengths

Return On Equity

Watchpoints

Return On Assets, Operating Margin, and Current Ratio

Key metrics snapshot

Return On Equity

28%

YoY: +49%

Industry median: -42% (n=671)

View history

Return On Assets

-806%

YoY: +37%

Industry median: -47% (n=669)

View history

Operating Margin

-350%

YoY: +133%

Industry median: -136% (n=304)

View history

Current Ratio

0.03x

YoY: +18%

Industry median: 3.43x (n=666)

View history

Quick Ratio

0.03x

YoY: +67%

Industry median: 1.99x (n=287)

View history

NetIncomeLoss YoY

-67%

YoY:

Industry median: 0.36% (n=639)

View history

Profitability

Metric Latest value YoY change
Return On Equity 28% +49%
Return On Assets -806% +37%
Operating Margin -350% +133%

Financial Health

Metric Latest value YoY change
Current Ratio 0.03x +18%
Quick Ratio 0.03x +67%
Debt-to-equity -1.04x -0.46%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY -67%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 108,054,704
Common Stock, Shares, Outstanding 108,054,704 +401%
Common Stock, Value, Issued $10,806 +401%
Weighted Average Number of Shares Outstanding, Basic 99,609,650 +2323%
Weighted Average Number of Shares Outstanding, Diluted 99,609,650 +2323%

Additional Metrics

Metric Latest value YoY change
Revenue from Contract with Customer, Excluding Assessed Tax $236,561 0%
Research and Development Expense $210,000
General and Administrative Expense $293,721 +391%
Operating Income (Loss) $828,786 -133%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,726,971 -66%
Income Tax Expense (Benefit) $0
Earnings Per Share, Basic 0.07 +92%
Earnings Per Share, Diluted 0.07 +92%
Cash and Cash Equivalents, at Carrying Value $4,578 +3291%
Accounts Receivable, after Allowance for Credit Loss, Current $232,298 +90%
Assets, Current $237,076 +36%
Assets $237,076 +24%
Accounts Payable, Current $11,024 -69%
Accrued Liabilities, Current $1,852,221 +8.5%
Liabilities, Current $6,810,073 +16%
Liabilities $6,810,073 +16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $222,580 -8.7%
Retained Earnings (Accumulated Deficit) $22,659,473 -8.2%
Stockholders' Equity Attributable to Parent $6,572,997 -16%
Liabilities and Equity $237,076 +24%
Other Noncash Income (Expense) $898,184 -32%
Increase (Decrease) in Accounts Receivable $27,425 +0%
Net Cash Provided by (Used in) Operating Activities $197,941 -198%
Net Cash Provided by (Used in) Financing Activities $132,964 +102%
Common Stock, Shares Authorized 5,800,000,000 0%
Common Stock, Shares, Issued 108,054,704 +401%
Common Stock, Par or Stated Value Per Share 0.0001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $64,977 -11084%
Deferred Tax Assets, Valuation Allowance $4,758,405
Deferred Tax Assets, Gross $4,758,405
Deferred Tax Assets, Operating Loss Carryforwards $4,758,405
Preferred Stock, Shares Authorized 800,000,000 0%
Additional Paid in Capital $16,297,234 +5.4%
Preferred Stock, Par or Stated Value Per Share 0.0001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%